随着新型抗生素在临床中的使用，囊性纤维化患者铜绿假单胞菌分离株的药敏性发生变化。
Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.
作者信息
Bosso J A, Allen J E, Matsen J M
机构信息
Department of Pharmacy Practice, College of Pharmacy, University of Utah, Salt Lake City 84112.
出版信息
Antimicrob Agents Chemother. 1989 Apr;33(4):526-8. doi: 10.1128/AAC.33.4.526.
Abstract
To detect a change in antibiotic susceptibility patterns in Pseudomonas aeruginosa isolates upon the introduction and clinical use of ciprofloxacin, aztreonam, and ceftazidime, MICs for clinical isolates collected before introduction of the antibiotics, during early clinical use, and later were determined for these and seven other antipseudomonal antibiotics. Concomitant resistance to two or more antibiotics was also studied. Over the three study periods, rates of susceptibility to 9 of the 10 antibiotics decreased. The largest decrease occurred with ceftazidime. Analysis of subsets of isolates from patients treated with ciprofloxacin or aztreonam also showed declining susceptibility to the latter but a stabilization of susceptibility to the former after an initial decline. Concomitant resistance within and among antibiotic classes was common.
摘要
为检测在环丙沙星、氨曲南和头孢他啶引入并临床使用后铜绿假单胞菌分离株抗生素敏感性模式的变化，测定了在这些抗生素引入前、临床早期使用期间及之后收集的临床分离株对这些抗生素以及其他七种抗假单胞菌抗生素的最低抑菌浓度（MIC）。还研究了对两种或更多种抗生素的同时耐药情况。在三个研究期间，10种抗生素中有9种的敏感率下降。头孢他啶的下降幅度最大。对接受环丙沙星或氨曲南治疗患者的分离株亚组分析也显示，对氨曲南的敏感性下降，但对环丙沙星的敏感性在最初下降后趋于稳定。抗生素类别内部和之间的同时耐药很常见。
相似文献
1
Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.随着新型抗生素在临床中的使用，囊性纤维化患者铜绿假单胞菌分离株的药敏性发生变化。
Antimicrob Agents Chemother. 1989 Apr;33(4):526-8. doi: 10.1128/AAC.33.4.526.
2
Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).铜绿假单胞菌对长期使用吸入用氨曲南（AZLI）的抗生素敏感性。
J Antimicrob Chemother. 2011 Oct;66(10):2398-404. doi: 10.1093/jac/dkr303. Epub 2011 Jul 22.
3
Comparison between the in-vitro activity of new agents on Pseudomonas aeruginosa isolates from cystic fibrosis patients and other chronic infections.新型药物对囊性纤维化患者和其他慢性感染患者分离出的铜绿假单胞菌的体外活性比较。
J Antimicrob Chemother. 1984 Jul;14(1):25-9. doi: 10.1093/jac/14.1.25.
4
Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in .Aztreonam 耐药性的进化是多因素的，并可能在. 中产生超毒力。
mBio. 2017 Oct 31;8(5):e00517-17. doi: 10.1128/mBio.00517-17.
5
Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.囊性纤维化中心的抗菌药物使用情况及铜绿假单胞菌药敏谱
Int J Antimicrob Agents. 2005 Mar;25(3):193-7. doi: 10.1016/j.ijantimicag.2004.11.009.
6
Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.依伐卡托是否会干扰常用抗生素对铜绿假单胞菌的抗菌活性？——一项体外研究的结果。
J Clin Pharm Ther. 2018 Dec;43(6):836-843. doi: 10.1111/jcpt.12722. Epub 2018 Jun 29.
7
8
In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.美国囊性纤维化患者初始分离的铜绿假单胞菌的体外抗生素敏感性
J Pediatric Infect Dis Soc. 2015 Jun;4(2):151-4. doi: 10.1093/jpids/pit052. Epub 2013 Sep 10.
9
Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.在使用氨曲南治疗囊性纤维化患者的过程中未出现快速产生的耐药性。
Diagn Microbiol Infect Dis. 1987 Sep;8(1):51-5. doi: 10.1016/0732-8893(87)90047-2.
10
In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.氨曲南、环丙沙星和头孢他啶联合用药对囊性纤维化患者铜绿假单胞菌和洋葱伯克霍尔德菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1990 Mar;34(3):487-8. doi: 10.1128/AAC.34.3.487.
引用本文的文献
1
Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.抗铜绿假单胞菌IgY抗体促进细菌调理作用并增强多形核中性粒细胞的吞噬活性。
Hum Vaccin Immunother. 2016 Jul 2;12(7):1690-9. doi: 10.1080/21645515.2016.1145848. Epub 2016 Feb 22.
2
Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.囊性纤维化患者抗生素治疗的优化。药代动力学考量。
Clin Pharmacokinet. 1993 Jun;24(6):496-506. doi: 10.2165/00003088-199324060-00005.
3
Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis.
J Clin Microbiol. 1993 Apr;31(4):788-92. doi: 10.1128/jcm.31.4.788-792.1993.
4
The emergence of antibiotic resistance: myths and facts in clinical practice.抗生素耐药性的出现：临床实践中的误区与事实
Intensive Care Med. 1990;16 Suppl 3:S206-11. doi: 10.1007/BF01709702.
5
Microbiology of airway disease in patients with cystic fibrosis.囊性纤维化患者气道疾病的微生物学
Clin Microbiol Rev. 1991 Jan;4(1):35-51. doi: 10.1128/CMR.4.1.35.
6
Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.对导致囊性纤维化患者抗生素治疗失败的铜绿假单胞菌菌株进行分子流行病学分析。
Eur J Clin Microbiol Infect Dis. 1992 May;11(5):432-7. doi: 10.1007/BF01961858.
本文引用的文献
1
Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis.阿洛西林用于囊性纤维化患儿铜绿假单胞菌所致的呼吸道感染
Chemotherapy. 1980;26(2):135-40. doi: 10.1159/000237895.
2
Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.多种β-内酰胺类药物和氨基糖苷类药物单独及联合使用时，对囊性纤维化患者分离出的铜绿假单胞菌菌株的活性。
Antimicrob Agents Chemother. 1982 Jun;21(6):939-43. doi: 10.1128/AAC.21.6.939.
3
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.氨曲南、哌拉西林和替卡西林联合阿米卡星对来自囊性纤维化患儿的耐阿米卡星铜绿假单胞菌和洋葱伯克霍尔德菌分离株的体外活性。
Antimicrob Agents Chemother. 1984 Feb;25(2):279-80. doi: 10.1128/AAC.25.2.279.
4
Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.三种抗生素治疗方案对囊性纤维化急性加重期的临床及细菌学反应：替卡西林-妥布霉素、阿洛西林-妥布霉素及阿洛西林-安慰剂。
J Infect Dis. 1983 Mar;147(3):559-67. doi: 10.1093/infdis/147.3.559.
5
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.头孢他啶与替卡西林及妥布霉素治疗囊性纤维化患者急性呼吸加重的对照试验。
Pediatr Infect Dis. 1985 Mar-Apr;4(2):172-7. doi: 10.1097/00006454-198503000-00012.
6
Antibiotic resistance of Pseudomonas species.
J Pediatr. 1986 May;108(5 Pt 2):830-4. doi: 10.1016/s0022-3476(86)80753-3.
7
8
Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.头孢他啶单药治疗与联合治疗在囊性纤维化患者铜绿假单胞菌肺部感染中的比较
Pediatr Infect Dis J. 1987 Jul;6(7):648-53. doi: 10.1097/00006454-198707000-00006.
9
Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
Pediatr Infect Dis J. 1988 Mar;7(3):171-6. doi: 10.1097/00006454-198803000-00008.
10
Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.在使用氨曲南治疗囊性纤维化患者的过程中未出现快速产生的耐药性。
Diagn Microbiol Infect Dis. 1987 Sep;8(1):51-5. doi: 10.1016/0732-8893(87)90047-2.
Zotero 插件